| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 0.12 | 33.3% |
| Total Income | 0.12 | 33.3% |
| Expenditure | 3.97 | 82.1% |
| PBT | -3.67 | 97.3% |
| Net Profit | -3.67 | 97.3% |
| OPM | — | |
| NPM | — | |
| EPS | -0.54 | 54.3% |
Lipocine Reports Q1 2026 Net Loss of $3.7 Million
07 May 2026 · 7 May, 6:36 pm
Summary
Lipocine Inc. announced its financial results for the first quarter ended March 31, 2026. The company reported a net loss of $3.7 million, or ($0.52) per diluted share, compared to a net loss of $1.9 million for the same quarter in the previous year. Royalty revenue from TLANDO sales increased to $119,000 from $94,000. As of March 31, 2026, Lipocine had $24.7 million in unrestricted cash, cash equivalents, and marketable investment securities.
Key Highlights
- 1
Lipocine had $24.7 million of unrestricted cash, cash equivalents and marketable investment securities as of March 31, 2026.
- 2
The company reported a net loss of $3.7 million, or ($0.52) per diluted share, for the quarter ended March 31, 2026.
- 3
Lipocine recognized royalty revenue from TLANDO sales of $119,000 during the quarter ended March 31, 2026.
- 4
Research and development expenses were $2.8 million for the quarter ended March 31, 2026.
- 5
General and administrative expenses were $1.2 million for the quarter ended March 31, 2026.
Informational and educational content only. Not investment advice.